Our mission - is to facilitate the transition of the Russian pharmaceutical market to develop into mature, be a guide on the course of development of the potential of all the pharmaceutical market participants, thereby improving the quality of life for the end user and society in general. Despite the relatively high susceptibility to Russia's external economic and financial risks, imbalances in the domestic policy and great social disparities, the pharmaceutical market in Russia has had a stable positive growth for the last few years.
Elena Maksimkina, the head of the drug supply department of the ministry, informed that the commission of the Ministry of Health of the Russian Federation on the formation of lists of medicines approved the inclusion of 60 new international non-patented names (INNs), 8 new dosage forms in the list of vital and essential medicines (VNIV), while two preparations were excluded from the list.
At the end of this year, the order of appearance of new drugs on the shelves should change. The Ministry of Health prepared a bill simplifying the issue of medicines in the civil circulation. Now the document is being discussed publicly, it is planned to adopt it before the end of the year.
As is known, from January 1 of the next year information on the interchangeability of drugs can be entered in the State Register of Medicines (GRLS). What will this mean for pharmaceuticals, medicine and, ultimately, for the patient? About the impact of the new rule on the health care system, says the head of the practice of "Healthcare" law firm "Pepeliaev Group" Sergei Klimenko.
According to the forecasts of the consulting company IPT Group, the volume of production of Russian pharmaceutical products by the end of this year will increase by 17-20% in physical terms, and in value terms - by 4-8%.
According to GlobalData, the US market for ultrasound equipment will increase to $ 5 billion by 2023 from $ 4.2 billion in 2016. At the same time, the cumulative annual growth rate will be 2.5%. The main factors of growth in this market segment will be an increase in the incidence and demand for affordable quality medical care.
According to the World Health Organization, rheumatic diseases cause 1/3 of all cases of temporary disability and about 10 percent of disability. It is extremely important that the disease affects, as a rule, middle-aged people, that is, the most able-bodied part of the population. This circumstance is an extremely acute socio-economic factor.
According to Rosstat, in July 2017, the consumer price index in Russia was 100.1%, since the beginning of the year - 102.4%. The consumer price index for medicines was 99.5%, since the beginning of the year - 98.4%, compared to July 2016 - 101.3%.